# Boryung Pharmaceutical

> Boryung Pharmaceutical is a VC fund in Seoul backing Medical and Health Care. See 6 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Seoul, South Korea
- Total investments: 6
- Last investment: Nov 2025
- Lead investor: 17%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/boryung/
- X (Twitter): https://twitter.com/boryungpharm
- Website: http://www.boryung.co.kr
- Facebook: https://www.facebook.com/boryungpharm

Boryung Pharmaceutical is a VC fund in Seoul focused on Medical and Health Care. Boryung, originally involved in pharmaceutical wholesale, transitioned into pharmaceutical manufacturing in 1963. Instead of simply being a drug manufacturer, the company decided to invest in the development of essential medicines for patients. This strategic shift paved the way for sustained growth in the pharmaceutical industry. Notably, in March2011, Boryung achieved a significant milestone by introducing "Kanarb," the first ARB (Angiotensin II Receptor Blocker) antihypertensive medication in South Korea.Looking ahead, in April 2022, Boryung is set to host the inaugural Care in Space (CIS) Challenge. This initiative demonstrates the company's commitment to exploring new horizons and aligns with its mission to become an indispensable contributor to human health in the era of space exploration. By embarking on this challenge, Boryung aims to discover fresh opportunities that can further its role in advancing human health, especially as technological advancements open up new frontiers.

## Contacts

5 contacts available for Boryung Pharmaceutical. Shizune tracks 1 team members at Boryung Pharmaceutical. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/boryung-pharmaceutical?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 33% |
| Health Care | 2 | 33% |
| Biotechnology | 2 | 33% |
| Software | 1 | 17% |
| Aerospace | 1 | 17% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 33% |
| Pre-Seed | 1 | 17% |
| Series C | 1 | 17% |
| Funding Round | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 33% |
| Luxembourg | 1 | 17% |
| United Kingdom | 1 | 17% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Jay Jung Gyun Kim | CEO | 1 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| LambdaVision | LambdaVision, Inc. is commercializing a retinal implant to restore vision for the millions of patients suffering from retinitis pigmentosa (RP) and age-related macular degeneration (AMD). | $7M | Seed | Nov 05, 2025 |  |
| Exobiosphere | Exobiosphere is a cutting-edge company operating at the intersection of space exploration and biotechnology. | $2.2M | Seed | Apr 04, 2025 |  |
| LambdaVision | LambdaVision, Inc. is commercializing a retinal implant to restore vision for the millions of patients suffering from retinitis pigmentosa (RP) and age-related macular degeneration (AMD). |  |  | May 29, 2024 |  |
| LambdaVision | LambdaVision, Inc. is commercializing a retinal implant to restore vision for the millions of patients suffering from retinitis pigmentosa (RP) and age-related macular degeneration (AMD). |  | Seed | May 29, 2024 |  |
| Axiom Space | Axiom Space is a space infrastructure company that develops commercial human spaceflight services and orbital platforms. It organizes private astronaut missions to the International Space Station, providing training, mission planning, and in-orbit support. The company is also building commercial space station modules intended to operateindependently in low Earth orbit. In addition, it develops spacesuits and spaceflight systems to support government and commercial customers. Its activities integrate mission operations, engineering, and space hardware development to expand access to space. | $350M | Series C | Aug 21, 2023 |  |
| MyelinZ | MyelinZ Group is redefining brain and body health with AI-driven neurotechnology. As the first Virtual Gym for the Brain, the company's three groundbreaking products (BodyMirror, SpaceMirror, and R-MMS) fuse neuroscience, AI, and gaming to unlock human potential on Earth and beyond. | $1.2M | Pre-Seed | Jan 26, 2023 |  |

6 of 6 investments shown.

## Co-investors
- [Aurelia Foundry](https://shizune.co/investors/profile/aurelia-foundry) — VC Fund, 3 deals together
- [E2MC Ventures](https://shizune.co/investors/profile/e2mc-ventures) — VC Fund, 3 deals together
- [Aljazira Capital](https://shizune.co/investors/profile/aljazira-capital) — VC Fund, 1 deal together
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund, 1 deal together
- Chenel Capital Partners — VC Fund, 1 deal together
- [Expansion Ventures](https://shizune.co/investors/profile/expansion-f37b) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Boryung Pharmaceutical invest in?

Boryung Pharmaceutical invests primarily in Medical, Health Care and Biotechnology startups, most often at Seed and Pre-Seed stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Boryung Pharmaceutical?

Public channels for Boryung Pharmaceutical include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Boryung Pharmaceutical?

The team at Boryung Pharmaceutical includes Jay Jung Gyun Kim (CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co